NBIX Q2 $959M: 3 Products Growing, 2027 Phase 3 Readouts

Neurocrine Biosciences (NBIX) just reported Q2 2026 revenue of $959 million, up 39% year-over-year. The stock closed at $185.50 on July 30, up from $180.79 the prior session. The market cap sits at roughly $18.1 billion. Three commercial products are generating accelerating revenue. The company raised Ingrezza guidance. And yet the entire investment thesis for 2027 comes down to two Phase 3 readouts that could redefine the company or remind everyone that neuroscience is the hardest field in drug development.

Q2 Results: Three Products, All Growing

The headline numbers are clean. Total revenue hit $959 million versus $688 million in Q2 2025, a 39% increase. Non-GAAP earnings per share came in at $2.85, up 73% from $1.65 a year ago. GAAP net income was $144 million ($1.39 per share).

The revenue breakdown tells the story of a company successfully transitioning from a single-product story to a multi-franchise neuroscience platform:

• Ingrezza (valbenazine, tardive dyskinesia): $716 million, up 15% YoY. Full-year guidance was raised from $2.7 to $2.8 billion up to $2.825 to $2.875 billion. The growth is driven by double-digit prescription volume increases in both total prescriptions (TRx) and new prescriptions (NRx). Ingrezza remains the dominant therapy in tardive dyskinesia, a market valued at $4.4 billion in 2025 across the seven major markets and growing at 8.1% annually.
• Crenessity (crinecerfont, congenital adrenal hyperplasia): $184 million, up 247% YoY. This is the growth engine. Reimbursement coverage reached approximately 80% of dispensed prescriptions in Q2, a critical milestone for a rare disease launch. The company also reported two-year Phase 3 CAHtalyst data showing positive growth outcomes in pediatric patients and improved cardiometabolic profiles in adults.
• VYKAT XR (diazoxide choline, Prader-Willi syndrome): $54 million from a partial quarter. The Soleno Therapeutics acquisition closed May 18, 2026, for $2.9 billion ($53 per share in cash). Pro-forma full-quarter sales were $94 million, suggesting a $350 to $400 million annual run rate for a product that has only been in Neurocrine’s hands for six weeks.

The Soleno Deal: Strategic but Pricey

The $2.9 billion Soleno acquisition is the elephant in the balance sheet. Cash dropped from $2.54 billion at year-end 2025 to $482 million at June 30, 2026. Neurocrine also entered a $1.0 billion revolving credit facility. The company recorded $2.2 billion in intangible assets related to VYKAT XR, amortized over 16 years.

The strategic logic is sound. VYKAT XR is the first and only approved therapy for hyperphagia in Prader-Willi syndrome, a rare disease with no other treatment options. At a $350 to $400 million run rate with limited competition, the acquisition price of $2.9 billion represents roughly 7 to 8x forward revenue. That is a premium but not unreasonable for a rare disease monopoly with first-mover advantage.

The concern is the balance sheet. $482 million in cash against $276 million in quarterly non-GAAP R&D spend and $305 million in quarterly non-GAAP SG&A means the company is burning cash while integrating a new product. The $1.0 billion credit facility provides a cushion, but Neurocrine is no longer the cash-rich biotech it was six months ago.

Pipeline: Two Phase 3 Readouts in 2027 That Determine Everything

The commercial portfolio is the floor. The pipeline is the ceiling. Two Phase 3 programs with readouts expected in 2027 will determine whether Neurocrine deserves a $25 billion valuation or a $12 billion one.

Osavampator (NBI-1065845) in major depressive disorder. This is an AMPA receptor positive allosteric modulator, a novel mechanism for depression. The Phase 2 SAVITRI study (NCT05203341) met its primary endpoint: a statistically significant reduction in MADRS total score at Day 28 versus placebo. At Day 56, the 1 mg dose showed a statistically significant improvement with an effect size of 0.73 (p=0.0016). An effect size of 0.73 in MDD is genuinely impressive. For context, most approved antidepressants show effect sizes in the 0.3 to 0.5 range on MADRS. The drug is being studied as an adjunctive therapy, meaning it is added to existing antidepressant treatment in patients with inadequate response.

The MDD market is enormous. Over 280 million people worldwide suffer from depression, and current treatments fail roughly one-third of patients. If osavampator’s Phase 3 replicates the Phase 2 effect size, Neurocrine has a drug that could generate $1 to $2 billion in peak sales. But MDD is also the graveyard of promising Phase 2 drugs. The history of neuroscience failures in depression is well documented, as we have analyzed in the context of Alzheimer’s drug failures. Phase 2 effect sizes routinely fail to replicate in Phase 3. The 0.73 effect size came from a 183-patient trial. Phase 3 will enroll thousands. That is the binary risk.

Direclidine (NBI-1117568) in schizophrenia. This is an oral, selective M4 muscarinic receptor agonist. The Phase 2 study met its primary endpoint: the 20 mg once-daily dose produced a 7.5-point improvement in PANSS total score versus placebo at Week 6 (p=0.011, effect size 0.61). The Phase 3 program is now enrolling (NCT07114874). The drug showed an 18.2-point PANSS reduction from baseline. Importantly, direclidine was well tolerated with minimal GI effects and no weight gain relative to placebo.

The competitive picture here is critical. Bristol Myers Squibb’s Cobenfy (xanomeline-trospium), approved in September 2024, is the first muscarinic agonist for schizophrenia. But Cobenfy is a dual M1/M4 agonist combined with a peripheral muscarinic antagonist to reduce side effects. Direclidine is M4-selective, meaning it targets only the M4 receptor without the M1 activation that drives GI side effects. This selectivity is the differentiator. BMS also reported that Cobenfy failed its Phase 3 ARISE trial as an adjunctive treatment, missing statistical significance versus placebo. That failure raises questions about the muscarinic class’s breadth, but it was an adjunctive study, not a monotherapy trial. We covered the Cobenfy launch context and BMS’s broader neuroscience strategy in our BMY Q2 earnings analysis.

The schizophrenia market is massive: 2.8 million patients in the US alone. Cobenfy’s approval validated the muscarinic mechanism. If direclidine’s selectivity translates to a cleaner side effect profile in Phase 3, Neurocrine could capture meaningful share. Peak sales potential in schizophrenia is $1.5 to $3 billion for a differentiated mechanism. We also covered the emerging muscarinic competitive picture in our MapLight ML-007 schizophrenia analysis.

Valuation: Pricing In Success

At $185.50, Neurocrine trades at a market cap of approximately $18.1 billion. The 2026 total revenue guidance implies roughly $3.8 to $3.9 billion. That breaks down to Ingrezza at a $2.85 billion midpoint, Crenessity tracking toward $700 million, and VYKAT XR contributing $200 million plus. Against that revenue base, the stock trades at approximately 4.7x forward revenue.

Compare that to Biogen (BIIB) at $30.9 billion market cap and 2.98x P/S. Biogen has a deeper commercial portfolio with Leqembi ramping, Spinraza and Skyclarys generating stable revenue, and a pipeline that includes Biogen Q2 growth-portfolio catalysts including Leqembi. Biogen trades at a lower revenue multiple because it faces generic competition on Tecfidera and slower Leqembi adoption. Neurocrine commands a premium because its growth rate is higher (39% vs Biogen’s mid-single digits) and its pipeline is more concentrated in high-value catalysts.

The analyst consensus price target sits around $193 to $194, roughly 4 to 5% above the current price. That tight gap tells you the Street has already priced in the commercial momentum. The upside scenario requires Phase 3 success in 2027.

Here is the framework. At $18.1 billion, the market is valuing the three commercial products at roughly $12 to $13 billion. That applies a 3.5x revenue multiple to ~$3.8 billion in 2026 revenue, consistent with large-cap neuroscience peers. That leaves $5 to $6 billion in pipeline option value. Osavampator in MDD at $1.5 billion peak sales and direclidine in schizophrenia at $2 billion peak sales, discounted at 10% over 4 years to launch plus ramp, justify $3 to $4 billion in net present value combined. The remaining $1 to $2 billion is the option value of the broader muscarinic platform and earlier-stage assets.

In other words, the stock is fairly valued if both Phase 3 programs succeed. It is overvalued if either fails. If both fail, the stock loses 30 to 40%, back to a pure commercial story at $110 to $120.

Risks

The primary risk is binary: Phase 3 failure. Osavampator’s 0.73 effect size came from 45 patients in the 1 mg arm. Phase 3 enrollment is larger and more diverse. Depression trials have a notoriously high placebo response rate that shrinks drug-placebo separation. The SAVITRI trial was 28 days for the primary endpoint. Phase 3 will test durability over longer periods.

Direclidine faces the same Phase 2-to-Phase 3 replication risk, plus a specific competitive concern. If Cobenfy’s ARISE adjunctive failure signals a broader limitation of muscarinic agonism, direclidine’s Phase 3 could underperform. The selectivity advantage (M4-only vs M1/M4 dual) is compelling but unproven at scale.

Secondary risks include the balance sheet. $482 million in cash is thin for a company spending $600 million quarterly on R&D and SG&A combined. The Soleno integration adds execution risk. Generic valbenazine could enter the market as early as 2027, pressuring Ingrezza’s growth trajectory right as the pipeline readouts arrive. For more on the broader neuroscience catalyst calendar, see our 2026 neuroscience biotech catalysts roundup.

Verdict

Neurocrine at $185 is a Hold. The commercial story is excellent: three products growing, Ingrezza guidance raised, Crenessity ramping at 247% YoY, and VYKAT XR adding a third franchise. But the stock is not cheap at 4.7x revenue when Biogen trades at 3.0x. The premium is justified only if you believe both Phase 3 readouts in 2027 will succeed.

The analysis does not bet on Phase 3 success before the data. The 0.73 effect size in MDD and the 0.61 effect size in schizophrenia are strong Phase 2 signals, but neuroscience has the highest Phase 3 failure rate of any therapeutic area. The BMY MeziKd PDUFA next May is a reminder that even good Phase 2 data does not guarantee approval.

The play is to wait. If osavampator’s Phase 3 reads out positive in early 2027, buy on the pullback that always follows a Phase 3 win in biotech (the “sell the news” effect). If it fails, the stock drops to $120 and you buy the commercial franchise at 3x revenue. Either way, $185 is not the entry point. The risk-reward is symmetric, and in biotech, symmetric means wait for the catalyst.